The human brain contains ~644 km of blood vessels that supply brain cells with oxygen, energy metabolites and nutrients and remove carbon dioxide and other meta bolic waste products from the brain to the systemic circulation 1,2 . Although representing only 2% of total body mass, the brain consumes ~20% of the body's glu cose and oxygen and can rapidly increase blood flow and oxygen delivery to its activated regions, a process known as neurovascular coupling 2, 3 . Capillaries are the smallest cerebral blood vessels (FIG. 1) ; they account for approximately 85% of cerebral vessel length and are a major site of the blood-brain barrier (BBB) 1 (FIG. 1) . In the human brain, capillaries provide approximately 12 m 2 of endothelial cell surface area, which is available for trans port of solutes from the blood to the brain and vice versa. The mean intercapillary distance in the human brain is ~40 μm (REF. 4); therefore, solute equilibration is almost instantaneous throughout the brain interstitial space once molecules cross the BBB.
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The endothelial BBB has tightly sealed celltocell con tacts that result in high transendothelial electrical resist ance and low paracellular and transcellular permeability 5 (FIG. 2) . The endothelial monolayer is sheathed by mural cells (pericytes in capillaries and vascular smooth muscle cells in arterioles and arteries) and by astrocyte endfeet 6, 7 . In contrast to the highly permeable systemic capillaries 8 , brain capillaries exhibit a low rate of transendothelial bulk flow by transcytosis, which together with the tightly sealed endothelium restricts the entry of most bloodderived molecules into the brain, unless they have specialized carriers and/or receptors in the brain endothelium that facilitate their transport across the BBB (FIG. 2) .
Maintaining BBB integrity is crucial for tight control of the chemical composition of brain interstitial fluid (ISF), which is critical for proper synaptic functioning, information processing and neuronal connectivity. Loss of BBB integrity results in increased vascular permeabil ity and is associated with reduced cerebral blood flow and impaired haemodynamic responses 2, 3, 5, 7, 9 . Breakdown of the BBB enables toxic bloodderived molecules, cells and microbial agents to enter the brain and is associated with inflammatory and immune responses, which can initiate multiple pathways of neurodegeneration.
In this Review, we first briefly describe the molecular architecture and transport physiology of the BBB and then examine vascular pathology and neuroimaging,
Tight junctions
Endothelial proteins that tightly connect brain endothelial cells and provide the anatomical blood-brain barrier with its low paracellular permeability and high transendothelial electrical resistance.
Transmembrane diffusion
A type of passive transport across a cellular membrane in which the net movement of molecules occurs down their respective concentration gradients.
Carrier-mediated transport (CMT) . Transport of molecules across the blood-brain barrier down their concentration gradients via specific membrane carrier proteins.
Receptor-mediated transcytosis
(RMT). Transport of molecules across the blood-brain barrier in a highly specific fashion via membrane receptors that become internalized with the ligand during transendothelial transcytosis.
postmortem and biomarker studies demonstrating BBB breakdown in several neurodegenerative diseases: Alzheimer disease (AD); Parkinson disease (PD); Huntington disease (HD); amyotrophic lateral sclerosis (ALS); and multiple sclerosis (MS), which is consid ered to be an autoimmune and neurodegenerative dis order 10 , in addition to HIV1associated dementia and chronic traumatic encephalopathy (CTE). We focus on the pathogenetic mechanisms by which BBB breakdown leads to neurodegeneration and briefly note the implica tions of BBB dysfunction for therapeutic drug delivery. Finally, we discuss future directions, gaps in the field and opportunities to control neurological disease by target ing the BBB. This Review does not examine the role of reduced cerebral blood flow and altered haemodynamic responses in AD and neurodegenerative disorders, nor does it cover BBB disruption in experimental models of AD and neuro degeneration, which have been extensively reviewed elsewhere 2, 3, 9, 11 . The BBB molecular architecture Brain endothelial cells are connected by tight junctions and adherens junctions. Tight junctions involve occlu din, claudin 1, claudin 3, claudin 5 and claudin 12 and the membraneassociated guanylate kinases, tight junction proteins ZO1, ZO2 and ZO3, whereas adhe rens junctions involve cadherins, platelet endothelial cell adhesion molecule (PECAM1) and the junctional adhesion molecules (JAMs) JAMA, JAMB and JAMC 6 . A paucity of pinocytosis and bulk flow fluid transcytosis contributes to the limited exchange of solutes across the brain endothelium (FIG. 2) , although oxygen and carbon dioxide rapidly diffuse across it. Small arterioles 12 and capillaries 13 are major sources of the brain's oxygen sup ply. Additionally, small lipidsoluble molecules and com pounds with a molecular weight <400 Da or containing <8 hydrogen bonds (such as ethanol) can cross the BBB by simple transmembrane diffusion 4 . Solute carrier-mediated transport (CMT) facilitates the transport of carbohydrates, amino acids, fatty acids, monocarboxylic acids, nucleotides, hormones, vitamins, organic anions and cations across the BBB. Receptormediated transcytosis (RMT) enables transendothelial transport of proteins and peptides in both directions: from blood to brain (transferrin and insulin) 4 and from brain to blood (apolipoproteins) 6 . Sodiumdependent lysophosphatidylcholine symporter 1 (NLS1, also known as major facilitator superfamily domaincontaining pro tein 2a), an important transporter, transports essential ω3 fatty acids into the brain 14 , which is also critical for BBB formation 15 
(FIG. 2).
The sodium pump (Na + /K + ATPase) on the ablu minal membrane of the BBB regulates sodium influx into the brain ISF in exchange for potassium 16 . Other ion transporters regulate the transport of sodium, potassium, chloride and calcium ions and facilitate the exchange of sodium for hydrogen ions and chloride for bicarbonate ions at the BBB. ATPbinding cassette (ABC) transporters expressed at the luminal side of the BBB prevent brain accumulation of drugs, xenobiotic agents and drug conjugates via active efflux from endothelium into blood 6, 17 . CMT facilitates CNStoblood clearance of excitatory amino acids (such as glutamate and aspar tate) 18 , whereas RMT clearance of amyloidβ (Aβ, some forms of which are associated with AD) 6, [19] [20] [21] [22] [23] [24] [25] across the BBB keeps brain levels of these potentially toxic sub stances low (FIG. 2) . Much more could be said about the molecular architecture of the BBB and its transport physiology, but only a brief overview is given here, as these topics have been reviewed in detail elsewhere 6, 7 . Molecules generated by the brain diffuse across brain extracellular spaces and are cleared from the brain by two mechanisms: transvascular transport across the BBB via the mechanisms illustrated in FIG. 2b-d ,f-h 5, 6, 26 and perivascular transport of ISF, which travels in the reverse direction to the flow of blood within the base ment membranes of arterial vessel walls [26] [27] [28] (FIG. 1) .
Studies conducted in the 1980s and 1990s showed that solutes carried by the perivascular ISF flow reach the sub arachnoid space, which is filled with cerebrospinal fluid (CSF) and drains into deep cervical lymph 29, 30 . In the past 3 years, further studies have confirmed a role of the dural lymphatic vascular system in clearance of ISF and macro molecules by the meningeal lymphatic vessels 31 , which drain into cervical lymph nodes [32] [33] [34] (FIG. 1) . Under physio logical conditions, the perivascular ISF pathway is responsible for 15-20% of the clearance of ADrelated forms of Aβ from the mouse brain 19, 35 , whereas 80-85% is removed by transvascular BBB transport. In 1985, solutes were shown to rapidly distribute throughout the brain by paravascular transport from the subarachnoid space through Virchow-Robin spaces, in the same direction as the flow of blood 36 . Subsequent studies introduced the term 'glymphatic' system to describe this paravascular circulation and suggested that solute transport in the CNS occurs via CSF convective flow through the brain extracellular spaces in a paraarterial to paravenous direction and is regulated by aquaporin 4 (AQP4) water channels on astrocytes 37, 38 . The proposed glymphatic mechanism, however, has not been supported by the latest studies [39] [40] [41] [42] , and the convective, pressuredriven fluid flow of CSF from paraarterial to paravenous extracellular spaces throughout the parenchyma remains unproved 39, 40, [43] [44] [45] . Furthermore, deletion of Aqp4 in mice and rats does not impair the transport of fluorescent sol utes from the subarachnoid space into the brain, which
Key points
• The blood-brain barrier (BBB) protects neurons from factors present in the systemic circulation and maintains the highly regulated brain internal milieu, which is required for proper synaptic and neuronal functioning • BBB breakdown facilitates entry into the brain of neurotoxic blood-derived products, cells and pathogens and is associated with inflammatory and immune responses, which can initiate multiple neurodegenerative pathways • Neuroimaging studies have demonstrated early BBB dysfunction in Alzheimer disease and other neurodegenerative disorders, which is also supported by biofluid biomarker data and is consistently observed in post-mortem tissue • BBB dysfunction in neurodegenerative disorders includes increased BBB permeability, microbleeds, impaired glucose transport, impaired P-glycoprotein 1 function, perivascular deposits of blood-derived products, cellular infiltration and degeneration of pericytes and endothelial cells
Cerebrospinal fluid (CSF) . A fluid continually produced in the choroid plexus that flows throughout the brain's ventricular system; it functions as a clearance pathway, maintains intraventricular intracranial pressure in the brain and is often analysed to measure levels of brain-derived biomarkers of disease.
Cerebral amyloid angiopathy
(CAA). In Alzheimer disease, amyloid deposition in the walls of small arteries and capillaries in the brain causes vascular degeneration and lobar microbleeds, which contribute to blood-brain barrier breakdown, infarcts, white matter changes and cognitive impairment.
implies that water production by astrocyte endfeet does not have a role in the regulation of solute transport within parenchymal extracellular spaces 39 . Further experimental work is needed to resolve these controversies.
Vascular pathology in neurodegeneration
Cerebrovascular dysfunction and vascular pathology contribute to cognitive decline and neuronal loss in AD in addition to ADrelated Aβ and tau pathology 5, 6, [46] [47] [48] [49] [50] [51] [52] [53] . Many lines of evidence indicate that cerebrovascu lar dysfunction in AD cannot be simply attributed to comorbid vascular dementia. For instance, in one study of the association between cerebrovascular and neuro degenerative disease, the US National Alzheimer Disease Coordinating Center database was used to identify 5,715 patients with an autopsybased diagnosis of a single neurodegenerative disease (AD, frontotemporal lobar degeneration, αsynucleinopathy, hippocampal sclerosis, prion disease or cerebrovascular disease) 52 . Within the subgroup of 4,629 patients diagnosed as having AD who had no evidence of mixed dementia, 80% had vascular pathology including cerebrovascular disease, lacunae and multiple microinfarcts indicative of small vessel disease, haemorrhage, atherosclerosis, arteriolosclerosis and cerebral amyloid angiopathy (CAA) 52 . The two sub groups of patients with an autopsybased diagnosis of either AD or cerebrovascular disease exhibited a remark ably similar prevalence of vascular risk factors, such as coronary disease, hypercholesterolemia and diabetes 52 . Cerebral vessel pathology is a major risk factor for AD dementia and is associated with low scores in most cognitive domains 51 . CAA, which is an important cause of BBB disruption and one of the three pathological hall marks of AD 54 , induces various vascular pathologies that contribute to cognitive decline 26 . Moreover, in preclini cal AD, changes in vascular biomarkers occur before the development of cognitive impairment and before detect able increases in standard AD biomarkers, including amyloid deposition, decreased CSF levels of Aβ42 (the most amyloidogenic form of Aβ) and increased CSF levels of tau and phosphorylated tau 48 . Small ves sel disease of the brain is prominent in patients with AD, as discussed below, and contributes to ~50% of all dementias worldwide 3, [55] [56] [57] [58] . 
Two-hit vascular hypothesis of AD
Blood vessel damage is thought to be the initial insult through which blood-brain barrier dysfunction and/or diminished brain perfusion lead directly to amyloid-β (Aβ)-independent secondary neuronal injury (first hit) and Aβ accumulation (second hit) in the brain owing to faulty Aβ clearance and increased antibody production.
E4 allele of apolipoprotein E
(APOE*ε4). This allele is the major genetic risk factor for sporadic late-onset Alzheimer disease.
According to the two-hit vascular hypothesis of AD, damage to blood vessels is the initial insult, causing BBB dysfunction and diminished brain perfusion that, in turn, lead to neuronal injury and Aβ accumulation in the brain 5, 6, 47, 50 . Cerebrovascular disruption is influenced by lifestyle and might act independently and/or syner gistically with Aβ to promote AD pathology, which is accelerated by genetic risk factors (such as carriage of the E4 allele of apolipoprotein E (APOE*ε4)), vascular risk fac tors (such as hypertension, diabetes and dyslipidaemia) and environmental risk factors (such as pollution) 47, 50 .
Vascular pathology also contributes to other neuro degenerative disorders 52 . For example, cerebrovascular disease plays a part in the pathogenesis of PD 52 , the second most common neurodegenerative disorder, which is characterized by accumulation of αsynuclein and degeneration of dopaminergic neurons in the sub stantia nigra. Vascular disease and vascular risk factors aggravate motor dysfunction and cognitive impairment in PD 59 . Cerebrovascular disease, BBB impairments and neurovascular abnormalities are also found in HD 60 Water is transported via aquaporin (AQP) receptors: AQP1 on endothelial cells and AQP4 on astrocyte end-feet. g | ATP-binding cassette (ABC) active efflux transporters limit entry of drugs, xenobiotic products and drug conjugates. h | Neurotoxic substances are cleared by phosphatidylinositol-binding clathrin assembly protein (PICALM)-mediated transcytosis and by LDL receptor-related protein 1 (LRP1), which removes toxic amyloid-β (Aβ) species linked to Alzheimer disease (AD). However, levels of receptor for advanced glycosylation end products (RAGE) are increased in AD, which promotes increased re-entry of circulating Aβ, thereby increasing brain Aβ levels. The CMT transporters, excitatory amino acid transporter 1 (EAAT1) and excitatory amino acid transporter 2 (EAAT2) clear neurotoxic glutamate and aspartate. i | Solutes diffusing across the brain extracellular spaces (ECS) (dotted arrows) are cleared via transvascular transport (as in parts c-e,g-i) and by perivascular ISF flow within the arterial wall in the reverse direction to blood flow, eventually reaching the CSF-filled subarachnoid space and draining into meningeal lymphatic vessels and cervical lymph nodes. ApoE, apolipoprotein E; ApoJ, apolipoprotein J.
Dynamic contrast-enhanced (DCE) MRI
A dynamic MRI sequence used to quantify regional bloodbrain barrier permeability to a gadolinium contrast agent. motor, cognitive, psychiatric and metabolic abnormali ties caused by the aggregation of mutant huntingtin pro tein. BBB disruption and trafficking of T cells, B cells and peripheral macrophages across the dysfunctional BBB are a pathological hallmark of MS 33 . BBB disruption has been described in ALS 62 , is a feature of CTE 63 and, in HIV1associated dementia, enables HIV1infected monocytes and macrophages to enter the brain 64 .
Neuroimaging evidence of BBB disruption
In this section, we examine recent PET and MRI studies of BBB integrity and function in AD and other neurodegenerative disorders (TABLE 1) .
Increased BBB permeability to gadolinium. BBB breakdown in the hippocampus, a centre of memory and learning, has been observed in dynamic contrastenhanced (DCE) MRI studies of individuals with mild cognitive impairment (MCI). In this technique, leakage of gadolinium contrast agent into the brain enables the regional CNS BBB permeability constant (K trans ) to be quantified using the Patlak analysis method 49, 65, 66 . A study that compared BBB breakdown in the hippocampus in individuals with MCI with that in agematched controls found that the extent of BBB breakdown was not affected by vascular risk factors 49 but correlated with increased CSF levels of soluble plateletderived growth factor receptorβ (PDGFRβ), a marker of pericyte injury 49, 67 . BBB breakdown in the hippocampus occurred before hippocampal atrophy 49 , which is typically seen early in AD 68, 69 , raising the possibility that BBB breakdown might precede neurodegeneration. This concept is supported by data from experimental models of BBB breakdown, which causes neurodegenerative changes over time [70] [71] [72] [73] . Followup DCEMRI studies in patients with early AD confirmed BBB breakdown in several grey matter and white matter regions 46, [74] [75] [76] (TABLE 1) . Consistent with these findings, early contrastenhanced MRI studies in humans showed increased BBB permeability in the hippocampus in individuals with MCI compared with healthy controls 77 and suggested that contrast agent accumulates in the brains of individuals with probable AD via a bloodtobraintoCSF pathway 78 . DCEMRI studies have found increased BBB leakage of gadolinium (quantified using the Patlak method 49, 65, 66 ) in the basal ganglia in patients with PD compared with healthy controls 79 . In patients with HD, DCEMRI ana lysis reveals a positive correlation between increased BBB permeability in the caudate nucleus and increased dis ease burden score as well as with increased grey matter arterial cerebral blood volume 60 . DCEMRI studies have similarly established the presence of increased BBB permeability in white matter in MS 49, [80] [81] [82] , particu larly in active MS lesions 83, 84 (TABLE 1) . Increased matrix metallo proteinase 9 (MMP9) activity in the CSF has been suggested to contribute to BBB breakdown in MS 82, 85 . To understand the pathogenetic role of BBB breakdown in the living human brain, future longitudinal DCE MRI studies are required to investigate the relationships between vascular changes, progression of neurological deficits in AD, PD, HD and MS and changes in brain structural and functional connectivity. Extending DCE MRI studies to patients with ALS, HIV1associated dementia and CTE will help us to identify whether regional BBB breakdown has a pathogenetic role in these neurodegenerative disorders.
Microbleeds. Damage to blood vessels can lead to pro nounced BBB breakdown manifested as cerebral micro bleeds (microhaemorrhages), which are frequently seen in AD [86] [87] [88] [89] [90] [91] [92] [93] , MCI 94 and in APOE*ε4positive individuals (who have an increased genetic risk of AD) 94 . CAA is one of the main causes of vascular degeneration and lobar microbleeds in AD and contributes to BBB breakdown, infarcts, white matter changes and cognitive impair ment 26 . Microbleed location is related to its aetiology: CAA causes lobar microbleeds, and hypertensive vas culopathy causes microbleeds in the basal ganglia, thala mus, cerebellum and brainstem (reviewed elsewhere 
CNS leukocyte infiltration (MMP inhibitor-PET)

MS Leukocyte infiltration (MMP activation) in lesions 143
AD, Alzheimer disease; ALS, amyotrophic lateral sclerosis; BBB, blood-brain barrier; DCE, dynamic contrast-enhanced; FDG, fluorodeoxyglucose; HD, Huntington disease; K trans , the regional CNS blood-brain barrier permeability constant; MCI, mild cognitive impairment; MMP, matrix metalloproteinase; MS, multiple sclerosis; PD, Parkinson disease; SWI, susceptibility-weighted imaging. (similar to CAAassociated microbleeds) and are mainly found in the occipital lobe 92, 98, 99 . Amyloid deposition in the brain, as detected by 18 Fflorbetapir PET, is positively associated with the number of microbleeds in individ uals with MCI and AD 99 . However, several studies that reported a high prevalence of microbleeds in patients with AD [86] [87] [88] [89] [90] [91] [92] [93] or MCI 94 did not perform amyloid PET imaging [86] [87] [88] [89] [90] [91] [92] [93] , precluding a direct comparison of microbleeds and CAA severity.
Cortical superficial siderosis (that is, detection of subpial deposits of haemosiderin) has been suggested as an alternative imaging biomarker for CAA 89, [100] [101] [102] . The extent of cortical superficial siderosis, lobar microbleeds and amyloid plaque burden is higher in patients with AD than in cognitively normal controls (as shown by MRI and amyloidPET studies 94 ), and MRI evidence of superficial siderosis was also observed in three individ uals with pathologically confirmed CAA. To definitively relate the topography and prevalence of microbleeds and superficial siderosis to CAA in AD, more amyloidPET and highfieldstrength MRI studies are needed, as discussed below.
Microbleeds are often used as a criterion to define small vessel disease in the brain 103 . Small hypointense regions on T2*-weighted and susceptibility-weighted imaging (SWI) MRI are thought to represent bloodderived haemo siderin deposits, probably phagocytosed by macro phages in the perivascular spaces after microbleeding events 96 . The strength of the MRI magnetic field deter mines the ability to detect brain microhaemorrhages 104 . For example, 3 T MRI studies indicate that approximately 45% of patients with AD 88, 90, 91, 94 and 25% of individuals with MCI 94 develop microhaemorrhages, whereas a 7 T MRI study found that 78% of patients with AD have microhaemorrhages 87 . Because most current studies involve 1.5 T and 3 T MRI, the incidence of microhaemor rhages in MCI and AD is likely to be underestimated. Highresolution confocal microscopy of brain tissue can detect capillary haemorrhages as small as 20-30 μm in diameter, which are easily missed on 1.5 T or 3 T MRI 62 . Cerebral microbleeds have been detected throughout deep grey matter regions (including the caudate, thala mus, putamen and globus pallidus), cortical regions and white matter in patients with PD by T2*weighted and SWIMRI. The incidence of microbleeds is higher in patients with PD dementia than in either PD patients without dementia or controls, and is associated with the extent of white matter lesions 105, 106 . Hypointense areas in the cortex on T2weighted MRI, which are suggestive of microbleeds, have also been shown in patients with ALS 62 . Studies using high resolution T2weighted 7 T MRI have also reported microbleeds in the brains and spinal cords of patients with ALS 107 . Impaired glucose transport. Glucose is a key energy substrate for the brain. Brain uptake of glucose is measured using the radiolabelled glucose analogue 18 F-fluorodeoxyglucose (FDG) as a PET tracer 46 . FDG enters the brain via solute carrier family 2, facilitated glucose transporter member 1 (also known as GLUT1), which is expressed only in the endothelium of the BBB and not in neurons 6, 108 . Besides GLUT1, brain uptake of FDG depends on cerebral blood flow 2, 5 , which is reduced in MCI and early AD before brain atrophic changes 2 . Although both glucose and FDG are rapidly trans ported into the brain via GLUT1, avidly taken up by brain cells and then phosphorylated by intracellular hexokinase 109, 110 , their subsequent metabolic fate in the brain is completely different 111 . Glucose6phosphate is metabolized rapidly in the glycolytic pathway, whereas FDG6phosphate is not a substrate for glucose 6phosphate isomerase and thus cannot be converted into fructose6phosphate, which precludes its fur ther metabolism 109, 110, 112, 113 . Therefore, approximately 45-90 min after systemic administration of FDG, 90-97% of this compound persists in the mouse 110 or rat 113, 114 brain in the form of FDG6phosphate or its epimers; the remainder is FDG. Brain cells have very low activity of glucose6phosphatase and poor trans port of FDG6phosphate across cell membranes 115, 116 ; thus, FDG6phosphate remains trapped within brain cells 114, 117 and is eliminated slowly from the brain. Because brain uptake of FDG across the BBB depends on GLUT1 and not on direct neuronal uptake, the diminished uptake of FDG in the AD brain points to a vascular defi cit (that is, impaired BBB function). Importantly, GLUT1 levels are substantially reduced in brain microvessels in AD [118] [119] [120] [121] . Diminished BBB transport and brain uptake of FDG precede neurodegeneration and brain atrophy in patients with MCI who later convert to a diagnosis of AD, as well as in patients with early AD. This vascular deficit should be considered in staging preclinical AD 122 . FDGPET studies also indicate that individuals with MCI have diminished glucose uptake in several brain regions (including the precuneus, posterior cingulate, right angular gyrus and bilateral temporal cortices) before any detectable neurodegenerative changes, brain atrophy and/or conversion to AD 123 . The reductions in FDG uptake in the posterior cingulate gyri and parieto temporal lobes of patients with AD are observed with and without corrections for partial volume effects, confirm ing that these decreases are not due to brain atrophy 124 . Longitudinal FDGPET findings have additionally sug gested that reductions in hippocampal glucose uptake during normal ageing can predict cognitive decline years in advance of a clinical AD diagnosis 125 . Similarly, asymptomatic carriers of presenilin 1 (PSEN1) mutations associated with earlyonset autosomal dominant AD show ADlike reductions in FDG uptake in the absence of brain atrophy 126 . Diminished glucose uptake in the hippo campus, parietotemporal cortex and/or posterior cingulate cortex has been repeatedly shown by FDG PET in early AD 127, 128 , in individuals at genetic risk of AD 129, 130 , in those with a positive family history of AD 131 and/or MCI and in individuals with no cognitive impair ment who went on to develop AD 132, 133 . The patterns of FDG brain uptake can also discriminate individuals with normal cognition from those with MCI and AD 127 . FDG PET changes preceding neurodegeneration are found not only in humans [123] [124] [125] [126] but also in transgenic mouse models of AD 134 , reflecting reductions in glucose transport across the BBB 135, 136 .
LDL receptor-related protein 1 (LRP1). The major efflux transporter for amyloid-β (Aβ) at the blood-brain barrier; it is responsible for brain-to-blood Aβ clearance.
Verapamil
An 11 C-radiolabelled PET ligand that enables the in vivo detection of P-glycoprotein 1 function at the blood-brain barrier in the living human brain.
Moreover, experimental studies in Slc2a1 +/-mice (which express 50% of GLUT1 levels in cerebral blood vessels compared with their wildtype littermates) have shown rapid BBB breakdown followed by secondary neurodegeneration, which is accelerated by Aβ 108 . No attempts have been made so far to explore whether GLUT1 at the BBB is a therapeutic target in human AD or whether pharmacological upregulation of this transporter in humans can prevent BBB breakdown, neurodegeneration and cognitive deficits, as it can in animal models. Additionally, the role of glucose trans port in other neurodegenerative disorders has not been examined and should be pursued by future studies.
Impaired P-glycoprotein 1 function. PGlycoprotein 1 (also known as multidrug resistance protein 1; encoded by ABCB1) mediates the active efflux of drugs and xenobiotic compounds from the endothelium to blood, thereby preventing their accumulation in the brain 6, 17 . Pglycoprotein 1 clears Aβ across the BBB, which requires LDL receptor-related protein-1 (LRP1) [137] [138] [139] . The function of Pglycoprotein 1 is clinically assessed by 11 CverapamilPET. VerapamilPET studies in AD have demonstrated increased uptake of verapamil in frontal, parietal, temporal and occipital cortices and in posterior and anterior cingulate gyri 140 . Similarly, verapamil PET studies in patients with mild AD found substantially reduced Pglycoprotein 1 activity in the parietotemporal, frontal and posterior cingulate corti ces and hippocampus 141 . Furthermore, verapamilPET studies indicated diminished Pglycoprotein 1 activity, which indicates BBB dysfunction, in the midbrain of patients with PD 142 . Collectively, these studies suggest that decreased Pglycoprotein 1 function is involved in the pathogenesis of AD -either by enabling xeno biotic compounds to accumulate in the brain (high levels of which can injure neurons and promote inflamma tion) and/or by reducing Aβ clearance across the BBB. Thus, Pglycoprotein 1 and LRP1 could be important therapeutic targets in AD, and perhaps also in PD.
CNS leukocyte infiltration. Studies using radiolabelled MMP inhibitors as PET tracers showed increased MMP activity in early MS lesions, which is associated with leukocyte infiltration 143 . Additionally, patients with MS show impaired cerebral venous drainage 144 and decreased cerebrovascular reactivity of grey matter, which corre lates with grey matter atrophy 145 . As leukocyte infiltra tion of the CNS also occurs in other neurodegenerative diseases, notably AD [146] [147] [148] [149] , HIV1associated dementia 150 and CTE 151 , similar MMPPET neuroimaging studies would be helpful to identify when in the course of these diseases this cellular infiltration of the CNS takes place. However, as yet, such studies are lacking.
Post-mortem evidence of BBB disruption
In this section, we examine the evidence of BBB disrup tion derived from analyses of postmortem tissues from patients with AD and other neurodegenerative dis orders. In these studies, BBB disruption is demonstrated by brain capillary leakages, degeneration of BBBassociated cells (including pericytes and endothelial cells), brain infil tration of circulating leukocytes and red blood cells, aberrant angiogenesis and molecular changes (TABLE 2) .
Capillary leakages. Several studies of postmortem brain tissue from patients with AD have found (using various analysis methods: immunohistochemistry, immuno blotting and Prussian blue staining) capillary leakages of bloodderived proteins in the prefrontal and ento rhinal cortex and hippocampus, including accumulations of fibrinogen, thrombin, albumin, IgG and iron containing proteins such as haemosiderin 146, 147, [152] [153] [154] [155] [156] [157] . These bloodderived proteins are often found colocalized with deposits of ADassociated Aβ 147, 153, 155 . Evidence of BBB breakdown is most pronounced in individuals carrying the APOE*ε4 allele, the major genetic risk factor for AD. By contrast, individuals homozygous for the most com mon allele, APOE*ε3, have a reduced risk of AD and show a decreased degree of BBB breakdown 147, 152, 156, 158 . As reviewed elsewhere 11 , multiple experi mental studies have confirmed that BBB breakdown causes capillary leakage in AD models of βamyloidosis [159] [160] [161] [162] and in APOE*ε4 transgenic mice 71, 163, 164 . Postmortem analysis of brain tissue from patients with PD revealed perivascular deposits of fibrinogen or fibrin 165 , IgG 166 and haemosiderin 165, 167 in the striatum, which is indicative of BBB breakdown. Fibrin(ogen) deposits around capillaries were also found in brain tissue from patients with HD 60 . Fibrinogen, thrombin, IgG and haemosiderin deposits have been found before the onset of motor neuron degeneration in brain and spinal cord tissue from patients with sporadic or famil ial forms of ALS 62, 107, 168 as well as in a transgenic mouse model of ALS 11, 169 . Finally, patients with MS develop capillary leakages of fibrinogen within active and inactive lesions, particu larly along vessels with abnormal tight junctions 170 . The first postmortem study of a patient with CTE found cerebral oedema and haemosiderinladen perivascular macrophages in the Virchow-Robin spaces 171 . Pericyte degeneration. Electron microscopy studies of brain tissue from patients with AD revealed pericyte degeneration in the cortex associated with large accu mulations of osmiophilic material. These changes are suggestive of increased phagocytosis of bloodderived proteins, mitochondrial alterations and an increased number of pinocytotic vesicles 172, 173 . Immunostaining for the pericyte marker PDGFRβ revealed reduced pericyte coverage and numbers on brain capillaries in brain sam ples from patients with AD 155 , which showed evidence of a genedose effect linked to the number of APOE*ε4 alleles (compared with homozygosity for APOE*ε3) 156 . Immunoassay of AD cortical tissue confirmed loss of the pericyte marker PDGFRβ in the precuneus 157 , a region affected early in the course of AD. Pericytes maintain BBB integrity 7, 174 , and their degeneration leads to BBB breakdown 70, 175, 176 . Additionally, pericytes clear Aβ from the brain, and their loss accelerates the onset and progression of Aβ and tau pathology in mouse models of AD 159 . 180 . A wide range of proangiogenic factors are also expressed in microvessels isolated from the brains of patients with AD 181 , which (in the presence of reduced MEOX2 expression) leads to reduced brain capillary density and cell death via increased expression of FOXO4 (which encodes fork head box protein O4, also known as forkhead domain transcription factor AFX1), which regulates apoptosis 180 . Pericytederived soluble factors that maintain a healthy endothelium might also be lacking in the AD brain owing to pericyte degeneration, which could poten tially contribute to endothelial degeneration, as shown in animal models 70 . Endothelial degeneration with microvascular changes (reductions in endothelial cell thickness, length and density), loss of and abnormalities in tight junc tion proteins and basement membrane changes have also been reported in brain tissue from patients with PD 166 . Immunohistological analysis of spinal cord or brain tissue from patients with ALS revealed endothe lial degeneration with reduced tight junctions, capillary basement membrane changes and enlarged perivascular spaces 168, 182, 183 as well as dissociation of astrocyte endfeet from capillaries 107 . Reduced expression of endothelial tight junction proteins claudin 5 and occludin has been shown in HD 60 . Endothelial degeneration with reduced and discontinuous expression of tight junction protein ZO1 has been shown in active and inactive MS lesions compared with in normalappearing white matter 170 . Postmortem studies of brain tissue from patients with HIV1associated dementia or HIV encephalitis have found evidence of microvascular degeneration and BBB breakdown, including reduced pericyte coverage 177 , reduced and disrupted tight junctions 150, 184 and capillary basement membrane changes 150 .
Cellular infiltration. Extravasation of red blood cells has been found in AD
146
, PD 165 and ALS
62
. Infiltration by peripheral macrophages has also been shown in AD 149, 172 and in HIV encephalitis 150 . Additionally, neutrophils can cross the BBB in AD 148 . These findings collectively sug gest that BBB breakdown in AD and other neurodegen erative disorders not only enables extravasation of red blood cells, which causes microbleeds and deposition of haemosiderin (derived from the haemoglobin carried by red blood cells), but also activates the innate immune response in the brain. Whether these immune system responses in nonAD neurodegenerative diseases are directed at identifying and eliminating pathogens that would otherwise enter the brain across the disrupted BBB (which in models of AD have been shown to accel erate amyloid deposition in exchange for circumscribing the infection process 185, 186 ) remains to be determined in future studies.
Aberrant angiogenesis. Increased levels of pro angiogenic factors have been reported in AD brains 181 . However, successful renewal of lost capillary networks is compromised in AD brains, which is probably a result of ongoing pericyte degeneration 7 and low endothelial expression of MEOX2 180 , as discussed above. Aberrant angiogenesis, as indicated by changes in markers of angio genesis, has also been found in the substantia nigra, locus coeruleus and putamen in PD 187, 188 . The effectiveness of deep brain stimulation of the subthala mic nucleus to alleviate motor symptoms in PD might even be attributable to improvements in the micro vascular architecture 189, 166 (such as increased capillary length and density or increased endothelial cell thick ness) along with increased expression of the tight and adherens junction proteins occludin, claudin 5, ZO1 and cadherin 5, and reduced perivascular IgG leakage, which have all been found in postmortem brain samples from patients with PD treated with deep brain stimulation compared with untreated patients with PD 166 . Detected by electron microscopy.
||
Detected by reverse transcription PCR.
Receptor for advanced glycosylation end products (RAGE). The major influx transporter of amyloid-β (Aβ) at the blood-brain barrier; it contributes to Aβ accumulation in the brain, the inflammatory response, suppression of blood flow and blood-brain barrier breakdown.
Increased density of capillaries (vessels 5-10 μm in diameter) and reduced numbers of larger microvessels (10-20 μm in diameter), suggestive of aberrant angio genesis, have been found in HD 60 . Abnormal vascular ization in the cortex and substantia nigra has also been found in HD 60, 61 .
Molecular changes.
Several studies have shown that AD brain endothelium expresses low levels of GLUT1, a BBBspecific glucose transporter [118] [119] [120] [121] , which leads to diminished glucose transport across the BBB 108 . AD brain microvessels also show diminished expres sion of LRP1, a major Aβ clearance receptor at the BBB 19, 20, 156, 190, 191 (a change that is also present in patients with hereditary cerebral haemorrhage with amyloid osis, Dutch type 20 ). Diminished LRP1 expression leads to reduced Aβ clearance from the brain, promoting its intracerebral accumulation 20, 22, 24 . Thus, LRP1 is a key target for improving transvascular Aβ clearance 192 . This mechanism could be important for the effectiveness of current Aβ clearance therapies based on antiAβ anti bodies, particularly for therapies with a peripheral Aβ sink mechanism of action, which requires Aβ clearance from braintoblood across the BBB [193] [194] [195] (FIG. 2) .
Patients with AD develop increased levels of receptor for advanced glycosylation end products (RAGE) in brain microvessels in both brain endothelium and mural cells 190, 191, 196 . RAGE transports Aβ in the opposite direction to LRP1, mediating the reentry of circulat ing Aβ into the brain, which promotes inflammation. Experimental studies have also identified RAGE as a major therapeutic target in AD [196] [197] [198] [199] , which led to initi ation of an ongoing phase III trial of a RAGE blocker in patients with AD 200 . Compared with controls, patients with AD have increased levels of both cyclophilin A (a proinflamma tory cytokine) and MMP9 in the brain endothelium and pericytes. These increases are particularly pronounced in APOE*ε4 carriers 156 , findings comparable to those in transgenic APOE*ε4 mice 71 , which suggests that these increases represent activation of a BBBdegrading path way involving cyclophilin A and MMP9. Activation of this cyclophilinA-MMP9 pathway has been confirmed by CSF analysis in nonsymptomatic APOE*ε4 carriers, in whom it is associated with BBB breakdown 201 , and by analysis of cyclophilin A mRNA levels in brain tissue 202 . As the cyclophilin A inhibitor alisporivir has shown promise in a phase III clinical trial as an addon treat ment for hepatitis C 203 , these studies raise the possibility that these agents might also be useful in stabilizing the BBB in APOE*ε4 AD carriers. Whether inhibition of the BBB cyclophilinA-MMP9 pathway can influence the neurodegenerative process in human APOE*ε4 carriers with AD (as it does in humanized APOE*ε4 transgenic mice 71 ) is an interesting topic for future studies. Postmortem studies of patients with HIV1 associated dementia or HIV encephalitis also report reduced expression of Pglycoprotein 1 in the brain endothelium 204 . Additionally, in patients with HD, mutant huntingtin aggregates accumulate in brain endothelial cells, perivascular macrophages, vascular smooth muscle cells and vascular basal lamina 60 and in genetically unrelated fetal neural allografts in the brains of patients with advanced HD 205 . These data suggest that the cerebral vasculature and immune system contrib ute to the spread of mutant huntingtin as well as to the ability of nonneuronal cells (including vascular cells) to contribute to spreading of the mutant huntingtin protein.
CSF evidence of BBB disruption
Here, we examine CSF biomarkers of BBB breakdown in AD and other neurodegenerative disorders (TABLE 3) . Other CSF biomarkers of aberrant angiogenesis, endothelial dysfunction, mural cell injury, inflamma tory cytokines and chemokines in AD and other neuro degenerative disorders have been reviewed in detail elsewhere 50, 206, 207 and are not examined here. Because albumin is a bloodderived protein, an increase in the ratio of CSF albumin to serum albumin levels, which is known as the albumin quotient (Qalb), is frequently used as a measure of BBB breakdown 50 . Qalb is reported to be elevated in several studies of individu als with preclinical AD 201 , MCI 49 and AD [208] [209] [210] , whereas other studies did not find any increase in Qalb in patients with AD 211 unless vascular risk factors (including mild arterial hypertension, diabetes mellitus, ischaemic heart disease 211, 213 or dyslipidemia 214 ) were also present. However, vascular risk factors are present in the major ity of patients with AD: 65% of patients aged 65 years and 80% of patients aged 85 years 3, 56, 57 . Although some studies have not specifically examined the relationship between vascular risk factors and Qalb 201, 208 , vascular risk factors did not worsen the extent of BBB breakdown as measured by gadolinium efflux from blood into the brain extravascular-extracellular space on DCEMRI K trans permeability analysis 49 . These observations sup port the view that BBB breakdown is associated with AD independently from vascular risk factors. Future studies should examine carefully whether ischaemic vascular damage from comorbidities and vascular risk factors 3, 47, 215 can augment BBB breakdown in AD. However, CSF albumin levels could be influenced by proteolytic cleavage as well as by albumin uptake by brain macrophages, microglia, astrocytes, neurons and oligodendrocytes (cells that express chondroitin sulfate proteoglycan 4 (also known as NG2) [216] [217] [218] . Therefore, Qalb might underestimate the degree of BBB break down. On the other hand, decreased CSF reabsorption and/or production could elevate Qalb, leading to false positive results that might not reflect BBB breakdown 206 .
In support of this notion, one study in seven patients with AD found that these individuals had a consider ably reduced rate of CSF production 219 . To determine definitively whether diminished CSF turnover under lies increased Qalb in some patients with AD, detailed human studies of CSF dynamics are needed. Sensitive tests of BBB integrity, including DCEMRI 49 , microbleed T2*weighted MRI 87 and/or measurement of alternative CSF bloodderived biomarkers (such as fibrinogen 220 and plasminogen 221 , which have previously been used to detect BBB breakdown in patients with MCI and early AD, respectively) should additionally be considered.
Several important CSF biomarker studies have reported increased Qalb 106, 209, 222, 223 as well as an increased CSF IgG:serum IgG ratio 222 in patients without demen tia who have earlystage PD compared with controls. Specifically, an independent study reported increased Qalb in 55 of 138 (~40%) patients with ALS (reviewed elsewhere 62 ). Increased CSF levels of albumin, IgG and other bloodderived proteins have also been reported in patients with ALS 62, 224 . Qalb is also elevated in patients with MS 218 , and this change correlates with increased white matter BBB permeability as detected by DCE MRI 80 . In patients with HIV1associated dementia, increased Qalb was associated with axonal injury as measured by CSF levels of neurofilament light chain 225 . Finally, increased MMP9 activity in CSF in patients with MS 82, 85 and in APOE*ε4 carriers before cognitive decline 201 is associated with BBB breakdown.
BBB breakdown and neurodegeneration
The neurodegenerative disorders discussed above share pathological alterations of the vessel wall resulting in BBB disruption. Endothelial degeneration leads to loss of tight junction proteins and/or increased transendothe lial bulk flow via transcytosis 5, 6 . The associated pericyte degeneration causes BBB breakdown 7, 70, [174] [175] [176] and initi ates multiple pathways of neurodegeneration (FIG. 3) owing to the entry of several neurotoxic bloodderived proteins, including plasminogen, thrombin and fibrin ogen, which enter different areas of the CNS in different neurodegenerative disorders (TABLES 1-3) .
Plasmin, which is generated from circulating plasminogen, degrades the neuronal matrix protein laminin, thereby promoting neuronal injury 226 . High concentrations of thrombin mediate neurotoxicity and memory impairment 227 and accelerate BBB dis ruption 228 . Fibrinogen leads to axonal retraction 229 and BBB damage, which promotes neuroinflammation 230 . Additionally, fibrin depletion delays the onset of neuro inflammation and demyelination in transgenic mouse models of MS 231 , and treatment with fibrin induced M1type activation and expression of antigen presenting genes in both primary microglia and bone marrow derived macrophages 232 . The roles of coagulation factors and fibrinolysis proteins in the development of brain pathology in MS has been reviewed elsewhere 233 . Influx of albumin leads to perivascular oedema, which obstructs the brain microcirculation and blood flow. In turn, these hypoxic conditions lead to neuronal injury and impaired haemodynamic responses that con tribute to neurodegeneration 2, 13 . Extravasation of red blood cells (microbleeds) is seen in almost all neuro degenerative disorders 92, 104 and leads to the perivascular accumulation of toxic, ironcontaining proteins (such as haemoglobin) that release Fe 2+ as they are broken down 107, 62, 73 , generating reactive oxygen species (ROS) and subjecting neurons to oxidative stress 234 .
In neurodegenerative diseases such as AD, PD and HIV1associated dementia [140] [141] [142] 204 , dysfunction of Pglycoprotein1mediated active efflux transport at the BBB leads to the accumulation of toxic xenobiotic agents (such as environmental pollutants, food addi tives, pesticides and drugs) in the brain. Reduced levels of Pglycoprotein 1 and LRP1 at the BBB 20, 25, 137 and increased levels of RAGE in brain microvessels 6, 190, 191, 196, 199 lead to faulty clearance of toxic Aβ species linked to AD and their accumulation in the brain. Both reduced blood flow and increased Aβ levels can promote tau pathol ogy, another key pathological hallmark of AD 2 . Whether faulty clearance of other proteins -tau in AD and CTE, αsynuclein in PD and/or huntingtin in HD -can also contribute to their respective accumulations in the CNS is not clear at present.
Interestingly, experimental studies suggest that αsynuclein is transported into and out of the brain across the BBB as a free peptide 235 . Moreover, systemi cally administered αsynuclein oligomers, ribbons and fibrils cause distinct synucleinopathies, implying that they can all cross the BBB 236 . In humans, extracellular vesicles containing αsynuclein have been found in the CSF and blood, suggesting bidirectional transport of this protein between the blood and CSF 237, 238 . As red blood cells are a source of αsynucleincontaining extracellular vesicles 237 and extravasation of red blood cells into the striatum has been detected in patients with PD 165, 166 , extravasated red blood cells might contribute to the development of αsynucleinopathy in humans. Because levels of αsynuclein are two orders of mag nitude higher in the circulation than in the CNS 238 , αsynuclein transport across the BBB might be impli cated in the pathogenesis of PD and could be a novel therapeutic target.
Accumulations of neurotoxic material and reduced blood flow can activate microglia and astrocytes, leading to an inflammatory response with secretion of neuro toxic cytokines and chemokines 47 . Additionally, in some diseases (such as AD), brain infiltration of peripheral macrophages 147, 149 and neutrophils 148 suggests activa tion of an innate immune response. Besides peripheral macrophage infiltration, influx of T and B lymphocytes across the BBB was found in patients with MS, indicating an adaptive immune response 33 . Altogether, these studies suggest that breakdown of the BBB enables the entry of circulating leukocytes into the brain.
BBB breakdown leads to the generation of several antiCNS autoantibodies in humans 239 , but their roles in the pathogenesis of neurodegenerative disorders have not been fully explored. Additionally, BBB breakdown can enable circulating pathogens to enter the brain and injure neurons and/or provoke an amyloid response that aggravates βamyloidosis, as has been shown in animal models of AD 185, 186 .
How BBB breakdown affects drug delivery Successful delivery of therapeutic agents across the BBB requires functionally and structurally healthy blood vessels, normal vascularization, adequate blood flow and recruitment of solute CMT or RMT systems to facilitate drug delivery to the CNS (FIG. 4) . Strategies that use existing CMT and RMT systems have been explored to increase brain penetration and potency of neurotherapeutic agents (FIG. 2) . For example, the large neutral amino acid CMT transporter delivers l3,4dihydroxyphenylalanine (lDOPA) to the brain in PD 240 , and the transferrin RMT can deliver therapeutic antibodies to the brain in various neurological condi tions 4, [241] [242] [243] . Other approaches to improve the delivery of therapeutic agents to the CNS have been attempted, such as using nanoparticles 244 and/or opening the BBB by focused ultrasound 245, 246 . Neurologists commonly assume that diseaseiniti ated BBB breakdown might present an opportunity to deliver treatments such as antibodies, proteins, peptides, small molecules and/or gene therapy to affected neurons without further need to manipulate the BBB. However, brain regions affected by neurodegeneration develop a pathological BBB breakdown characterized by functional and structural changes in the blood vessels, which often develop before neurodegeneration and persist as the dis ease progresses. These vascular changes include endothe lial degeneration, reduced expression of tight junctions and adherens junctions at the BBB, increased endothelial bulk flow transcytosis, disrupted BBB transporter expres sion, pericyte degeneration, perivascular accumulation of toxic products, inflammation and immune responses (FIG. 3) , which all hinder the delivery of therapeutic agents to the brain. Under pathological conditions, blood derived products, water and electrolytes accumulate in the enlarged perivascular spaces, and interfere with the normal diffusion of solutes across brain extracellular spaces, ISF formation and ISF flow, resulting in impaired distribution of solutes throughout the CNS (FIG. 4) . As a consequence of diseasedriven BBB disruption, impaired solute transport across parenchymal extracellular spaces and diminished ISF regional flow, therapeutic agents (including antibodies, proteins, peptides and small mol ecules) are likely to get trapped in pathologically altered brain tissue within the enlarged perivascular spaces along with other bloodderived debris, preventing them from reaching their neuronal targets. The decreased function of CMT and RMT systems in neurodegenerative diseases additionally complicates their use for therapeutic drug delivery. Therefore, brain regions with healthy blood vessels and/or stabilization of the damaged vasculature in diseaseaffected brain regions are needed to improve cerebrovascular integrity and reestablish diffusion across extracellular spaces and ISF circulation, factors that are important for the successful delivery of neurotherapeutic agents to diseaseaffected brain tissue.
Insight from gene and protein studies BBB breakdown is also found in (rare) inherited mono genic neurological disorders involving a primary genetic deficit in brain endothelial cells and/or mural cells of the vascular wall 6 . For example, mutations in SLC2A1 (which encodes GLUT1) lead to GLUT1deficiency syndrome, which is characterized by the onset of seiz ures in infancy, microcephaly, mild movement disorder and developmental delay 247 associated with early onset of BBB breakdown 108 . Mutations in MFSD2A (which encodes NLS1, the brain endothelial transporter of essential ω3 fatty acids) lead to lethal or nonlethal micro cephaly, cognitive disorder, spasticity, absent speech 248, 249 and early BBB breakdown 15 . Mutations in SLC16A2 (which encodes monocarboxylate transporter 8 (MCT8), a protein that transports thyroid hormones into the CNS) lead to Allan-Herndon-Dudley syndrome with severe psychomotor retardation 250 . Mutations in OCLN (which encodes the tight junction BBB protein occlu din) lead to earlyonset seizures, microcephaly and grey matter calcification, whereas mutations in JAM3 (which encodes JAMC, another tight junction BBB protein) lead to brain haemorrhages and subependymal calcifications due to leakage from the BBB 251, 252 . Mutations in PDGFRB (which encodes PDGFRβ) in pericytes lead to BBB breakdown and cause a primary familial brain calcifi cation characterized by earlyonset microvascular calci fication in basal ganglia, which induces seizures, motor impairment and cognitive problems 253, 254 . Despite their rarity, the known genetic aetiologies of these diseases offer valuable insights into the shared causal mechanisms underpinning BBB defects and neuro degeneration 255 . In addition, researchers are developing an advanced RNA sequencing molecular atlas of the BBB and its associated cells in animal models 6, 256 ; similar studies in humans are desirable to understand the functions of the human BBB at the molecular level.
Conclusions and future directions
In this Review, we position BBB breakdown as a key path ogenic feature of neurodegenerative diseases (TABLES 1-3). However, in contrast to the inherited monogenic diseases described above 6, [247] [248] [249] [250] [251] [252] [253] [254] , we have limited knowledge of the molecular mechanisms underlying BBB breakdown in nonmonogenic human neurodegenerative disorders. Most mechanistic insights have been gained from animal models of these disorders 6, 11 . The development of advanced brain imaging tech niques holds considerable promise for future neuro vascular research in humans. These new techniques are capable of interrogating changes in BBB integrity in regions as small as hippocampal subfields 46, 49, 65, 66 , and use highstrength 7 T magnets that increase the detectabil ity of vascular changes 87, 104 such as decreased regional cerebral blood flow and haemodynamic responses 2 , enlarged perivascular spaces 55 and the incidence and distribution of microbleeds. The development of new molecular ligands (in addition to the currently used amyloid and tau PET ligands for AD 255 , FDGPET [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] [133] and verapamil PET [140] [141] [142] ) for use in other neurodegener ative dis orders -for example, ligands to visualize MMP activity at the BBB in vivo 143 and/or the activity of other BBB transporters, receptors and junctional proteins affected by disease processes -is expected to provide important mechanistic insights into the role of the brain vascular system in neurodegeneration.
Besides the key question -what exactly is the role of the vascular system in the pathogenesis of neurode generative disorders, dementia and motor CNS changes? -emerging fields of research relate to the prognostic and diagnostic value of neurovascular imaging and molecular biomarkers in predicting neurodegenerative processes and cognitive decline. Development of new biomarkers of vascular injury and/or repair in CSF and blood, and studies to determine how they relate to other systemic and cellspecific biomarkers of the neurovascu lar unit (including astrocyte, neuronal, oligodendrocyte, microglial and inflammatory biomarkers and/or stand ard disease biomarkers, such as Aβ and tau in AD 50 ) are expected to advance our understanding of vascular contributions to neurodegeneration and dementia.
Clearly, a healthy brain needs a healthy vascular sys tem for its normal functioning. If CNS vascular changes really do drive the initial pathogenic events that con tribute to the onset and progression of neurodegenera tion, loss of brain connectivity and neuronal injury and loss in complex neurodegenerative disorders -as they do in human monogenic disorders of the BBB 6 -we also need to know whether therapeutic targeting of the BBB can arrest or even reverse the course of neurological disorders in humans, as has been shown in some animal models 71, 73, 192, 196, 199 . New treatments are needed to stabi lize vascular function in patients with neurodegenerative disorders as are new drug delivery methods that target the BBB. In this regard, development of in vitro human BBB models derived from induced pluripotent stem cells (iPSCs) from patients with different neurodegenerative disorders, including genetic and sporadic forms of these diseases, is expected to advance drug discovery.
Finally, how genetics, vascular risk factors, environ ment and lifestyle interact to influence the function of the BBB during normal ageing and in neurological dis ease is another important direction for future studies. Going forward, BBB breakdown should be therapeuti cally targeted in combination with other approaches to prevent, arrest and ultimately reverse neurodegenerative processes and clinical deficits.
RNA sequencing
A transcriptomic approach to reveal the presence and quantity of RNA transcripts in a biological sample.
Induced pluripotent stem cells
(iPSCs). Adult cells reprogrammed to induce an embryonic-like pluripotent state for the purposes of inducing differentiation into a cell type of interest for research studies and/or potential therapeutic efforts.
